MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• MoonLake Immunotherapeutics (NASDAQ:MLTX) has received a consensus rating of "Moderate Buy" from analysts, with seven out of nine brokerages recommending to buy.
• The company's average 12-month price target is $74.43, with Goldman Sachs recently raising their price objective from $74.00 to $82.00.
• MoonLake's quarterly earnings report showed an EPS of ($0.87), which was lower than analysts' expectations of ($0.73).

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $74.4286.

A number of equities research analysts recently commented on the stock. Needham & Company LLC reissued a "buy" rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Redburn Atlantic raised shares of MoonLake Immunotherapeutics to a "hold" rating in a research report on Monday, July 28th. Royal Bank Of Canada reissued an "outperform" rating and set a $67.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 3rd. Rothschild & Co Redburn assumed coverage on shares of MoonLake Immunotherapeutics in a research report on Monday, July 28th. They set a "neutral" rating and a $65.00 target price for the company. Finally, The Goldman Sachs Group raised their price target on shares of MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in MLTX. Paradigm Biocapital Advisors LP lifted its stake in shares of MoonLake Immunotherapeutics by 90.3% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company's stock worth $95,965,000 after buying an additional 840,731 shares during the period. Nuveen LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the first quarter worth $26,308,000. Polar Capital Holdings Plc lifted its stake in shares of MoonLake Immunotherapeutics by 120.0% during the fourth quarter. Polar Capital Holdings Plc now owns 1,100,000 shares of the company's stock worth $59,565,000 after buying an additional 600,000 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of MoonLake Immunotherapeutics by 12.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company's stock worth $181,059,000 after buying an additional 363,394 shares during the period. Finally, Vestal Point Capital LP lifted its stake in shares of MoonLake Immunotherapeutics by 175.0% during the second quarter. Vestal Point Capital LP now owns 550,000 shares of the company's stock worth $25,960,000 after buying an additional 350,000 shares during the period. 93.85% of the stock is currently owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Stock Up 1.7%

NASDAQ:MLTX traded up $0.95 during midday trading on Monday, reaching $55.75. 607,821 shares of the stock traded hands, compared to its average volume of 416,945. MoonLake Immunotherapeutics has a 12-month low of $31.42 and a 12-month high of $58.26. The business has a 50-day moving average of $51.68 and a two-hundred day moving average of $44.10. The company has a debt-to-equity ratio of 0.21, a quick ratio of 16.65 and a current ratio of 16.65. The stock has a market capitalization of $3.58 billion, a PE ratio of -20.05 and a beta of 1.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same quarter in the prior year, the firm earned ($0.39) EPS. On average, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.